Efficacy and safety of intrapatient dose escalation of sorafenib as first-line treatment for metastatic renal cell carcinoma (mRCC).

被引：17

作者：

Gore, M. E.

Jones, R. J.

Ravaud, A.

Kuczyk, M.

Demkow, T.

Bearz, A.

Laferriere, N.

Strauss, U. P.

Porta, C.

机构：

[1] Royal Marsden Hosp, London SW3 6JJ, England

[2] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland

[3] Hop St Andre CHU, Bordeaux, France

[4] Hannover Med Sch, D-30623 Hannover, Germany

[5] Inst M Sklodowskiej Curie, Ctr Onkol, Warsaw, Poland

[6] IRCCS Ctr Rif Oncol, Pordenone, Italy

[7] Bayer HealthCare, Wuppertal, Germany

[8] Bayer, Leverkusen, Germany

[9] IRCCS Policlin San Matteo, Pavia, Italy

来源：

关键词：

D O I：

10.1200/jco.2011.29.15_suppl.4609

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4609

引用

页数：1